Cambridge, Mass.-based Voluntis has developed an FDA-approved system, Insulia, which provides automated insulin dose recommendations that can be monitored remotely by a patient’s healthcare team. WellDoc’s BlueStar program gives real-time, individualized coaching to people with Type II diabetes.
The companies expect to launch discussions with health systems and health plans in the second half of the first quarter this year.
“We are excited to be working with WellDoc so that we can bring together extensive coaching and actionable insulin titration recommendations,” Voluntis CEO Pierre Leurent said in prepared remarks. “By bringing both products and these capabilities under the same umbrella, we hope to further simplify treatment for people living with Type II diabetes.”
“We are pleased to announce this significant commercial agreement with Voluntis and believe that our two organizations greatly complement each other,” WellDoc president & CEO Kevin McRaith added. “Together, we will be able to provide a combined solution that providers, health systems, and health plans can offer to their members with type 2 diabetes.”